Product nameAnti-Biotin antibody (HRP)
See all Biotin primary antibodies
DescriptionGoat polyclonal to Biotin (HRP)
Tested applicationsSuitable for: ELISA, WB, ICCmore details
Biotin conjugated to KLH
Molar enzyme/antibody protein ratio is 4:1.
Storage instructionsShipped at 4°C. Store at +4°C.
Storage bufferpH: 7.10
Preservative: 0.01% Thimerosal (merthiolate)
Constituents: 1.19% HEPES, 0.58% Sodium chloride
Concentration information loading...
PurityImmunogen affinity purified
- TMB ELISA Substrate (Highest Sensitivity) (ab171522)
- TMB ELISA Substrate (High Sensitivity) (ab171523)
- TMB ELISA Substrate (Fast Kinetic Rate) (ab171524)
- TMB ELISA Substrate (Slow Kinetic Rate) (ab171525)
- TMB ELISA Substrate (Slower Kinetic Rate) (ab171526)
- TMB ELISA Substrate (Slowest Kinetic Rate) (ab171527)
- 450 nm Stop Solution for TMB Substrate (ab171529)
- 650 nm Stop Solution for TMB Substrate (ab171531)
- Immunoassay Blocking Buffer (ab171534)
- Immunoassay Blocking (BSA Free) (ab171535)
Our Abpromise guarantee covers the use of ab19221 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
ICC: 1/200 - 1/500.
Not tested in other applications.
Optimal dilutions/concentrations should be determined by the end user.
RelevanceBiotin is a water soluble vitamin, generally classified as a B complex vitamin, also called vitamin B4. After the initial discovery of biotin, nearly forty years of research were required to establish it as a vitamin. Biotin is required by all organisms but can only be synthesized by bacteria, yeasts, molds, algae, and some plant species. Biotin is required as prosthetic group of enzymes involved in incorporation of carbon dioxide into organic compounds. Biotin has a MW of 244 Da.
- Vitamin B4 antibody
This product has been referenced in:
- Wei W et al. Soluble Frizzled-7 receptor inhibits Wnt signaling and sensitizes hepatocellular carcinoma cells towards doxorubicin. Mol Cancer 10:16 (2011). WB . Read more (PubMed: 21314951) »
- Bühler P et al. Influence of structural variations on biological activity of anti-PSMA scFv and immunotoxins targeting prostate cancer. Anticancer Res 30:3373-9 (2010). WB . Read more (PubMed: 20944111) »